JP2010246565A5 - - Google Patents

Download PDF

Info

Publication number
JP2010246565A5
JP2010246565A5 JP2010167648A JP2010167648A JP2010246565A5 JP 2010246565 A5 JP2010246565 A5 JP 2010246565A5 JP 2010167648 A JP2010167648 A JP 2010167648A JP 2010167648 A JP2010167648 A JP 2010167648A JP 2010246565 A5 JP2010246565 A5 JP 2010246565A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
cdr
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010167648A
Other languages
English (en)
Japanese (ja)
Other versions
JP5528246B2 (ja
JP2010246565A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010246565A publication Critical patent/JP2010246565A/ja
Publication of JP2010246565A5 publication Critical patent/JP2010246565A5/ja
Application granted granted Critical
Publication of JP5528246B2 publication Critical patent/JP5528246B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010167648A 2006-06-02 2010-07-26 肝細胞成長因子(hgf)結合蛋白質 Expired - Fee Related JP5528246B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US60/810,714 2006-06-02
US86046106P 2006-11-21 2006-11-21
US60/860,461 2006-11-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009513297A Division JP4560582B2 (ja) 2006-06-02 2007-06-01 肝細胞成長因子(hgf)結合蛋白質

Publications (3)

Publication Number Publication Date
JP2010246565A JP2010246565A (ja) 2010-11-04
JP2010246565A5 true JP2010246565A5 (enExample) 2010-12-24
JP5528246B2 JP5528246B2 (ja) 2014-06-25

Family

ID=38802082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009513297A Expired - Fee Related JP4560582B2 (ja) 2006-06-02 2007-06-01 肝細胞成長因子(hgf)結合蛋白質
JP2010167648A Expired - Fee Related JP5528246B2 (ja) 2006-06-02 2010-07-26 肝細胞成長因子(hgf)結合蛋白質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009513297A Expired - Fee Related JP4560582B2 (ja) 2006-06-02 2007-06-01 肝細胞成長因子(hgf)結合蛋白質

Country Status (15)

Country Link
US (5) US7659378B2 (enExample)
EP (2) EP2380908A1 (enExample)
JP (2) JP4560582B2 (enExample)
KR (1) KR101196184B1 (enExample)
AR (1) AR061170A1 (enExample)
AT (1) ATE533787T1 (enExample)
AU (1) AU2007254853B2 (enExample)
BR (1) BRPI0712223A2 (enExample)
CA (1) CA2654019A1 (enExample)
ES (1) ES2378097T3 (enExample)
IL (2) IL195038A0 (enExample)
MX (1) MX2008015138A (enExample)
NO (1) NO20085422L (enExample)
NZ (1) NZ573819A (enExample)
WO (1) WO2007143098A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659378B2 (en) * 2006-06-02 2010-02-09 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
CA2654025C (en) * 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
HUE027154T2 (en) 2007-07-02 2016-08-29 Oncomed Pharm Inc Preparations and procedures for the treatment and diagnosis of cancer
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
AU2009241589B2 (en) * 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2725873C (en) 2008-05-29 2018-05-01 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
NZ589434A (en) * 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
HUE028589T2 (en) * 2008-07-10 2016-12-28 Toray Industries Pharmaceutical preparation for the treatment and prevention of cancer
US8101723B2 (en) 2008-11-07 2012-01-24 Galaxy Biotech, Llc Monoclonal antibodies to fibroblast growth factor receptor 2
JP2012508563A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 抗IGF1R発現の増強のためのβGl−IGGイントロン
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012004710A2 (pt) * 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
PH12012500691A1 (en) 2009-10-15 2012-11-12 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR082461A1 (es) 2010-08-03 2012-12-12 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2013002270A (es) 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.
US20130236467A1 (en) 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
EP2964673A4 (en) * 2013-03-14 2017-02-22 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
EP3180027A4 (en) * 2014-08-15 2018-01-10 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
ES2822228T3 (es) * 2014-10-24 2021-04-29 Univ Leland Stanford Junior Composiciones y métodos para inducir la fagocitosis de células positivas de clase I de CMH y contrarrestar la resistencia a anti-CD47/SIRPA
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
JP7366388B2 (ja) 2016-03-28 2023-10-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗Ryk抗体およびその使用方法
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
EP3634486A4 (en) 2017-06-05 2021-03-31 Janssen Biotech, Inc. GENETICALLY PRODUCED MULTISPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS OF THE CH2-CH3 REGION
WO2018232188A1 (en) * 2017-06-15 2018-12-20 Memorial Sloan Kettering Cancer Center Anti-l1-cam antibodies and uses thereof
IL319835A (en) 2017-12-06 2025-05-01 Avidity Biosciences Inc Compositions and methods for treating muscular dystrophy and myotonic dystrophy
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
CA3133633A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
CA3148713A1 (en) 2019-08-12 2021-02-18 Interna Technologies B.V. New treatments involving mirna-193a
US20230136088A1 (en) 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death
MX2022011880A (es) 2020-03-27 2022-10-20 Avidity Biosciences Inc Composiciones y metodos para tratar distrofia muscular.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US8609090B2 (en) 2003-07-18 2013-12-17 Amgen Inc. Specific binding agents to hepatocyte growth factor
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체
KR20080026562A (ko) 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US7659378B2 (en) * 2006-06-02 2010-02-09 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
CA2654025C (en) 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-hgf/sf 인간화 항체 및 이의 제조방법

Similar Documents

Publication Publication Date Title
JP2010246565A5 (enExample)
JP2013520984A5 (enExample)
JP2009297037A5 (enExample)
RU2012147591A (ru) Антитела к erbb3
JP2010538608A5 (enExample)
TW201441263A (zh) 控制重組蛋白質中之c端離胺酸、半乳糖、及涎酸含量的製造方法
JPWO2019173291A5 (enExample)
JP2012525829A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2010148652A (ru) Фармацевтические композиции с устойчивостью к растворимому сеа
JP2015506912A5 (enExample)
JP2012523848A5 (enExample)
JP6827255B2 (ja) 血管内皮リパーゼの酵素活性を阻害するヒト化モノクローナル抗体
JP2012526558A5 (enExample)
RU2009126766A (ru) Антитела человека к дельта-подобному лиганду-4 человека
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2014524733A5 (enExample)
GB2517953A (en) Antibodies to complex targets
JP2013539369A5 (enExample)
JP7328324B2 (ja) Tim-3に対する抗体およびその使用
KR20180041136A (ko) 항-epha4 항체
JP2015508056A5 (enExample)
JP2025165991A (ja) 腎疾患における抗幹細胞因子抗体及びその使用方法
JP2013519690A5 (enExample)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)